PresentationThank you for standing by, and welcome to the AVLAYAH FDA Approval Call. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Laura Hansen, Vice President of Investor Relations. Please go ahead.Laura Hansen Thank you, Jonathan, and good day, everyone. Thank you for joining us today for our AVLAYAH FDA Approval Conference Call. I'm Laura Hansen, Vice President of Investor Relations at Denali Therapeutics. Joining me ...

Denali Therapeutics (NasdaqGS:DNLI) Update / briefing March 25, 2026 12:30 PM ET Company ParticipantsAlexander Schuth - CFO and COOAndrew Tsai - Managing DirectorJohn Kreger - Director of ResearchKatie Peng - Chief Commercial OfficerLaura Chico - Managing Director of Equity ResearchLaura Hansen - VP of Investor RelationsLydia Erdman - Biotech Equity Research AssociateMayank Mamtani - Senior Managing Director and Group Head of HealthcareMike Riad - VPPeter Chin - Chief Medical OfficerPeyton Bohnsack - VP of ...

Denali Therapeutics (NasdaqGS:DNLI) Update / briefing March 25, 2026 12:30 PM ET Speaker8Reminder, today's program is being recorded. Now I'd like to introduce your host for today's program, Laura Hansen, Vice President of Investor Relations. Please go ahead.Speaker4Thank you, Jonathan, and good day, everyone. Thank you for joining us today for our AVLAYAH FDA approval conference call. I'm Laura Hansen, Vice President of Investor Relations at Denali Therapeutics. Joining me on the call today are Ryan Watts, ...